NCT06972472

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 600 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO. Participation in the study will last about 18 months.

Conditions

• Obesity
• Overweight
• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Orforglipron	Administered orally
DRUG	Placebo	Administered orally

Timeline

• Start date: 2025-05-19
• Primary completion: 2027-01-01
• Completion: 2027-08-01
• First posted: 2025-05-15
• Last updated: 2025-11-04

Locations

77 sites across 7 countries: United States, Argentina, China, Czechia, Germany, Japan, Puerto Rico

Regulatory

• FDA-regulated drug study